Guest User
New Draft Guidance on Protocol Deviation ...

01/21/2025

-

The guidance breaks down the roles and responsibilities of the investigator, sponsor, and Institutional Review Board (IRB) in regards to monitoring, mitigating, reporting, and evaluating protocol deviations (PDs). The investigator, who is responsible for the conduct of the trial and protection of the rights, safety, and welfare of the participants must report all PDs to the sponsor, highlighting the important PDs.

New Draft Guidance on Protocol Deviation Management Part 2/2
Guest User
ICH E6(R3) Progresses into Step Four

01/15/2025

-

On January 6, 2025, the International Council of Harmonisation’s ICH E6(R3) for Good Clinical Practices (GCP) reached step four of the formal ICH procedure. This means that the ICH E6(R3) draft guidelines, since its release in May of 2023, were submitted to and approved by the ICH Regulatory Members of the ICH Assembly for adoption as an ICH Harmonised Guideline replacing E6(R2).

ICH E6(R3) Progresses into Step Four
Guest User
New Draft Guidance on Protocol Deviation ...

01/14/2025

-

On December 30, 2024, the US Food and Drug Administration (FDA) released the draft guidance for industry titled “Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices” to help trial sponsors, investigators, and institutional review boards (IRB) define, identify, and report protocol deviations.

New Draft Guidance on Protocol Deviation Management Part 1/2
Guest User
Implementing the New UK Clinical Trials ...

01/07/2025

-

The Health Research Authority (HRA) announced that England and Wales have begun implementing changes to their clinical trial regulations on June 1st, 2024. These changes include the removal of the requirement for trials to submit annual progress report to their Research Ethics Committee (REC) and the process of submitting safety reports. Scotland and Northern Ireland, following review, also implemented these changes to their regulations making the updates now applicable in all four of the UK nations as of August 1st, 2024.

Implementing the New UK Clinical Trials Regulations
Guest User
ICH E6(R3) Annex 2 Draft Version is Now ...

12/23/2024

-

On November 6th, 2024, the International Council of Harmonization (ICH) published the draft version of ICH E6(R3) Annex 2, a long awaited update to the good clinical practice (GCP) section of the ICH Harmonized Guidelines.

ICH E6(R3) Annex 2 Draft Version is Now Available!

Draft GDPR Adequacy Decision for UK

3/02/2021

-

When the Brexit transition period ended at the end of 2020, the United Kingdom (UK) officially left the European Union (EU) single market and customs union. This means that for the purposes of the General Data Protection Regulation (Regulation (EU) 2016/679 or GDPR), the UK is a third country with regards to data transfer. As a third country, personal data transfers require additional safeguards. At the beginning of 2021, the EU-UK Trade and Cooperation Agreement came into effect. A part of this Agreement includes a provision which allows data transfers to continue without additional mechanisms until an adequacy decision is adopted, for a maximum of six months.

Sam Sather a Speaker and Panelist at SCOPE Virtual Summit for Clinical Ops Executives

2/23/2021

-

Topic for Speaking Engagement and Panel Discussion: Central and Remote Monitoring: Leveraging Central and Remote Monitoring in Risk-Based Quality Management

Topic for Panel Discussion: Medical Device Trial Regulations, Quality and Data Management: Navigating a Changing Regulatory Landscape and Accelerating Approvals

Dates: March 2 - 4, 2021

Location: The virtual summit consists of pre-recorded sessions with live panel discussions and live Q&A sessions.

Register: https://register.healthtech.com/reg/scope

Sandra “SAM” Sather is:

Is Your Study High Quality? Investigator Warning Letter Issued

2/16/2021

-

During the pandemic, onsite FDA inspections were temporarily suspended starting in March 2020 and restarted late summer. Our blog “FDA Resumes Domestic Inspections” describes the risk-based approach to remote assessments during that time period. This in part explains the long interval since the last warning letter. The first new warning letter after inspections resumed was issued to an investigator.

Now Available for Purchase: CRO Oversight Training

2/09/2021

-

Sponsors outsourcing clinical trials tasks is nothing new, but how does the sponsor ensure CROs and vendors understand which duties or activities they are conducting and how to provide quality services? Regulatory authorities require sponsors to oversee the quality of the work that CROs or vendors working on behalf of the CROs complete. Good oversight means a supportive partnership that should be established and defined early on. Introduction to CRO Oversight lecture video training is now available for purchase in our online store HERE.

ISO 14155:2020 Clinical Leader Article & Medical Device GCP Training

02/02/2021

-

Our article “An ISO 14155:2020 Primer — Good Clinical Practice for Medical Device Trials” was recently published in the Clinical Leader HERE. Following is some background.

The International Organization for Standardization (ISO) is composed of a network of national standard bodies that do not describe country-specific requirements and is the world’s largest developer of voluntary standards. Its goal is for the applicable industries to be more efficient and effective. International standards give specifications for products, services, and good practice. ISO standards help ensure global consistency in a variety of areas and industries, including clinical trials. Although the standards are voluntary, some regulatory authorities or companies require an ISO standard to be followed.